...
首页> 外文期刊>BioMed research international >A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs
【24h】

A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs

机译:以环糊精为载体的化学治疗细胞毒性抗癌药物的综述

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Most of the cytotoxic chemotherapeutic agents have poor aqueous solubility. These molecules are associated with poor physicochemical and biopharmaceutical properties, which makes the formulation difficult. An important approach in this regard is the use of combination of cyclodextrin and nanotechnology in delivery system. This paper provides an overview of limitations associated with anticancer drugs, their complexation with cyclodextrins, loading/encapsulating the complexed drugs into carriers, and various approaches used for the delivery. The present review article aims to assess the utility of cyclodextrin-based carriers like liposomes, niosomes, nanoparticles, micelles, millirods, and siRNA for delivery of antineoplastic agents. These systems based on cyclodextrin complexation and nanotechnology will camouflage the undesirable properties of drug and lead to synergistic or additive effect. Cyclodextrin-based nanotechnology seems to provide better therapeutic effect and sustain long life of healthy and recovered cells. Still, considerable study on delivery system and administration routes of cyclodextrin-based carriers is necessary with respect to their pharmacokinetics and toxicology to substantiate their safety and efficiency. In future, it would be possible to resolve the conventional and current issues associated with the development and commercialization of antineoplastic agents.
机译:大多数细胞毒性化学治疗剂的水溶性差。这些分子与较差的物理化学和生物药物特性有关,这使配制困难。在这方面,一种重要的方法是在递送系统中结合使用环糊精和纳米技术。本文概述了与抗癌药物相关的局限性,它们与环糊精的复合作用,将复合药物加载/封装到载体中以及各种用于递送的方法。本文的目的是评估基于环糊精的载体,如脂质体,脂质体,纳米颗粒,胶束,毫微颗粒和siRNA在抗肿瘤药中的应用。这些基于环糊精络合和纳米技术的系统将掩盖药物的不良特性,并导致协同或累加效应。基于环糊精的纳米技术似乎可以提供更好的治疗效果,并维持健康和恢复细胞的长寿命。仍然需要对基于环糊精的载体的递送系统和给药途径进行大量研究,以证实其药代动力学和毒理学,以证实其安全性和有效性。将来,有可能解决与抗肿瘤药的开发和商业化有关的常规和当前问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号